Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling - Wikidata - awgldk - TriplyDB

Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling

Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling

http://www.wikidata.org/entity/Q35742331

about

Somatic mutations in disorders with disrupted brain connectivity In Vivo Delivery Systems for Therapeutic Genome Editing Brain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the future Applications of CRISPR-Cas systems in neuroscience The CRISPR revolution and its impact on cancer research Genetically engineered mouse models in oncology research and cancer medicine Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia.CRISPR/Cas9: Transcending the Reality of Genome Editing.Annexin A2 Modulates ROS and Impacts Inflammatory Response via IL-17 Signaling in Polymicrobial Sepsis Mice.piggyBac mediates efficient in vivo CRISPR library screening for tumorigenesis in mice Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling.CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs Rapid tumor induction in zebrafish by TALEN-mediated somatic inactivation of the retinoblastoma1 tumor suppressor rb1 Tissue-specific tumorigenesis: context matters.PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme.Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery.Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS.CRISPR/Cas9-induced disruption of gene expression in mouse embryonic brain and single neural stem cells in vivo.Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice.CNS Tumors in Neurofibromatosis.Therapeutic genome engineering via CRISPR-Cas systems.The application of somatic CRISPR-Cas9 to conditional genome editing in Caenorhabditis elegans.The application of CRISPR technology to high content screening in primary neurons.TALENs and CRISPR/Cas9 fuel genetically engineered clinically relevant Xenopus tropicalis tumor models.The big bang of genome editing technology: development and application of the CRISPR/Cas9 system in disease animal models The present and future of genome editing in cancer research.Applications of the CRISPR/Cas9 system in murine cancer modeling.Somatic Engineering of Oncogenic Chromosomal Rearrangements: A Perspective CRISPR: a versatile tool for both forward and reverse genetics research.In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS.Development of zebrafish medulloblastoma-like PNET model by TALEN-mediated somatic gene inactivation.Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells."CRISPR" validation of recessive brain cancer genes in vivo.CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas.

P2860

Q26747309-64F0AEA1-A21A-439A-A50A-F1E49AFA44D5 Q26748886-4A1F67FA-D103-4D97-9CBE-1EDB9DD18D54 Q26753206-AC205776-2C6B-4D59-B437-8D3E234714D8 Q26776515-75408A71-7F5E-44A3-9FC0-F310C6BAE53E Q26824997-6C347470-A7AE-498E-A34E-CA7BEE03F62C Q28079323-7513B984-6B34-4AFA-BB0A-ADB45F7041F5 Q30274618-99FD535A-0C7B-4762-8272-44323D8C4228 Q33632925-B8090C61-1C1F-41BA-AE82-BF320398E29E Q36070617-33A8F159-E9F4-4F27-80AD-6BFFB1D26EEC Q36243531-F0889150-EDD3-4D33-A23C-39A978429E3C Q36245097-EAEC8787-E862-4E1B-A1EA-0FBD1C75E3E4 Q36250079-F8412301-0668-4A14-B558-A09BE2B8D229 Q36273681-1F51CF8D-7976-46EA-B33D-B8D0C8B620A2 Q36296335-DDD5E9E5-B580-44A7-9325-3102B93A21C2 Q36392356-B2825575-217F-4050-854B-EF1949F6081E Q36771546-1B3C2455-C1D5-4100-A2A8-3461F6CBAB98 Q37051766-2C3CFF52-D9E5-4EB5-BD75-269E7D89BF03 Q37330941-38181D79-6944-4BB2-A7C8-6FBFCCB8A7D2 Q37719291-D64281C6-ED14-4645-B7B2-76D7DECABE0C Q38682882-B1041FA9-E33E-431D-A5B6-6F13716EAD13 Q38687781-F3E29595-5EBD-412A-937C-20641A683AB8 Q38699787-F87500DA-D932-4C81-BE1E-E751842677D6 Q38707232-285073C1-65B5-4971-B968-0488F8D3FB3A Q38713914-D97017F2-659D-4D90-B8EB-634BACE69407 Q38757432-A8416CE9-1EFD-4335-A56C-9EEF40C954B9 Q38757952-7533C48C-0B6D-4E95-B1C1-B6BF893755E8 Q38767473-6F8E8877-AEC3-4E03-A440-79DF7BD43401 Q38769494-BE46B406-E1B2-452C-A0C5-6C45079CB3D7 Q38836751-E0DF3078-6E4A-4BDC-9396-F42D22041DF3 Q38840267-7715B195-1A2F-4AD9-9043-05C60DF9748B Q38858314-44560AB9-A607-4465-8A01-99E0CFC2FD85 Q38926441-F1FBB3AC-9149-4984-9887-D53A47F16FF2 Q39627059-8131A131-6CBD-45E0-90D3-3EF45821BDAE Q40263108-F398CDF2-8785-4DA5-B56D-1BE993BF0BCC Q40829178-81403E7C-DD61-4F3B-B088-C53EC7971FC9 Q41548915-ACC8AE9E-93C5-4FD9-8CBE-CBD28AB2B9B1 Q41701616-D61060A8-D741-4D9A-91D7-353B1CB38501 Q42605129-563CBBC4-5108-4D79-9F72-0EC0573D42FE Q47141255-8C05F69C-0453-439D-B92B-432BAACF15DF Q47436402-ABA90AB2-60A6-482D-84CF-71C374CEC17B

P2860

Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling

http://www.wikidata.org/entity/Q35742331

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling

@ast

Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling

@en

type

label

Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling

@ast

Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling

@en

prefLabel

Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling

@ast

Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling

@en

P1433

Q35742331-4CAA5C5C-FECB-4FED-8680-88F406A77223

P1476

Q35742331-D284D04A-A986-45FD-9D0A-5CC6B90FF83C

P2093

Q35742331-3F997A60-485E-4516-AC59-B1474BD56DFE

Q35742331-440CFDD1-61A7-4E2B-B52A-2F414DB84B85

Q35742331-54D65C9A-E58F-429F-BEC5-F2D799D03A15

Q35742331-61FAC056-DC84-4A4E-A7CF-9933B4E626B4

Q35742331-64957D69-6D4D-4F1B-B50B-B1FC13239745

Q35742331-87F1FEE9-11DB-4A91-AE31-75326102C2A5

Q35742331-90E1B377-644F-41D1-9AED-AF447E1623B6

Q35742331-AF75D5C0-C17B-43D5-AEF8-22F4CDCC9F3F

Q35742331-CCA3F6AF-3608-432A-B607-6C6EB6E316FE

Q35742331-DF1CFFE5-E7CF-4287-846F-832E6A7B620E

P2860

Q35742331-01B4CA53-C07E-4E75-9853-B18D97A5CDCA

Q35742331-031B9E75-369E-4153-9CFB-3D8473E9C775

Q35742331-087AFB5C-723D-4F8F-BB17-F6018FDF8FC9

Q35742331-08C9A680-51EC-4C31-A7BC-2E4FA4FAE511

Q35742331-08CFEEAF-BA23-4A7C-9583-EB1E87E1EE46

Q35742331-0997B2AB-0406-4CBD-BA45-82B1D3D05E1D

Q35742331-0D34DF88-DACD-4C43-B0CF-BB57F59D0484

Q35742331-12991005-C5FD-4E14-BFB2-3392C9A7F5B0

Q35742331-14F89B3C-EFD2-4DA3-856D-5236636DCF49

Q35742331-17865E50-6DCB-4110-AEEA-97A7E759CB5B

P2888

Q35742331-9095C4B6-8C8A-4FBD-AE3D-05A1600F32D1

P304

Q35742331-CEC179D7-86DF-4B49-A611-B1E52A4F329D

P31

Q35742331-CEF42257-C01B-4874-BA29-15F1C81BC859

P356

Q35742331-F1275207-27D2-436C-95DF-FDE79844AA22

P407

Q35742331-0886115F-9B59-4D48-93A3-D5ED47DF1AD8

P478

Q35742331-CFA9351E-950F-41A3-BFA3-53BBF360A31E

P50

Q35742331-0B950A8F-AC0A-4C03-BDF7-75A53AB8EA0E

Q35742331-3FC39359-34C3-4D19-BBFB-FA3D582F5170

Q35742331-4819459B-0D59-4C01-A59E-F74907CBB5EA

Q35742331-5D178B4B-DCF3-49BA-AB4C-711D5F306E6B

Q35742331-C156E062-8B60-4B62-A2A1-361DFEE91C36

P577

Q35742331-CB9DE266-7700-47CB-965D-345EF7F48B13

P5875

Q35742331-7EDB119F-F00A-4DCD-98A5-BB7259C9526B

P698

Q35742331-CD633373-6A49-4B12-8D96-71F1D7C9E446

P921

Q35742331-A24C7C3A-A52C-422C-B9C7-DE5AA666B1CE

P932

Q35742331-4E2629C2-A8E7-492D-BF6B-28D45D2427A0

P356

P1433

Nature Communications

P1476

Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling

@en

P2093

Andrey Korshunov

http://www.w3.org/2001/XMLSchema#string

Barbara Tschida

http://www.w3.org/2001/XMLSchema#string

Branden Moriarity

http://www.w3.org/2001/XMLSchema#string

Christiane B Knobbe-Thomsen

http://www.w3.org/2001/XMLSchema#string

Daisuke Kawauchi

http://www.w3.org/2001/XMLSchema#string

David Largaespada

http://www.w3.org/2001/XMLSchema#string

David T W Jones

http://www.w3.org/2001/XMLSchema#string

Jan Gronych

http://www.w3.org/2001/XMLSchema#string

Jelena Belic

http://www.w3.org/2001/XMLSchema#string

Kathrin Schramm

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation and mechanisms of mammalian double-strand break repair

RNA-guided human genome engineering via Cas9

Multiplex genome engineering using CRISPR/Cas systems

Molecular subgroups of medulloblastoma: the current consensus

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition

RNA-programmed genome editing in human cells

Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease

The somatic genomic landscape of glioblastoma

P2888

P304

7391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS8391

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Guido Reifenberger

Stefan M Pfister

Martine F Roussel

Volker Hovestadt

P577

2015-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278033601

http://www.w3.org/2001/XMLSchema#string

P698

26067104

http://www.w3.org/2001/XMLSchema#string

P921

P932

4467376

http://www.w3.org/2001/XMLSchema#string